Eric Lefkofsky’s newest venture is Tempus Labs Inc. The company is a medical startup that is exploring a unique approach to medicine. Now, under the leadership of Eric Lefkofsky, Tempus may be considering going public. It is believed that the medical startup may offer an IPO as early as the first half of 2022. However, it’s always possible for plans to change. 

The company has seen many successful fundraising attempts since its creation. As of December 2020, Tempus medical research firm was valued at over $8 billion after raising $200 million in equity. They also gained $250 million in convertible debt. Eric Lefkofsky informs that several notable people and companies have already invested in Tempus, making the possibility of an IPO even more likely. Google, Novo Holdings, and Baillie Gifford are just a few of the high-profile names that have already invested in Tempus. 

About Tempus

Led by Eric Lefkofsky, Tempus was founded in 2015 and proceeded to build the world’s largest collection of clinical and molecular data. The company’s focus is on its work with Cedars-Sinai Cancer in an attempt to develop personalized treatment by using replicas of protein, DNA, and RNA.  Jennifer Doudna was recently added to Tempus’s growing board, attempting to bring experienced members to their leadership team. Eric Lefkofsky points out, Jim Rogers was also promoted to chief financial officer. 

More on Eric Lefkofsky´s biography and career at http://lefkofsky.com/blog/